Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia

A myelofibrosis and tumor-related technology, which is applied in the field of treatment of myelofibrosis and anemia related to myeloproliferative tumors, can solve the problems of short duration of response medium, shortened splenectomy survival time, and aggravated anemia.

Pending Publication Date: 2020-04-21
CELGENE CORP
View PDF26 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, hydroxyurea treatment will aggravate anemia, and long-term use may have mutagenic problems. Splenectomy has a shorter duration of response medium, which may shorten the survival period after splenectomy, and the postoperative morbidity is higher. Allogeneic hematopoietic stem cell transplantation may lead to leukemic transformation (Sochacki et al., 2016, Therapeutic approaches in myelofibrosis and myelodysplastic / myeloproliferative overlapsyndromes, Onco Targets Ther, 2016(9):2273-286)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia
  • Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia
  • Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 2

[0192] 6.2.1 background

[0193] Myeloproliferative neoplasms (MPN)-associated myelofibrosis (MF) is a clonal myeloid neoplasm characterized by myelofibrosis, defective bone marrow function, extramedullary hematopoiesis, propensity to blastocyst transition, and inflammation (Mesa RA et al. LeukRes. 2011;35(1):12-13). Anemia and red blood cell (RBC) transfusion dependence (TD) are independent poor prognosis and survival predictors in these patients (Passamonti F et al. Blood. 2010; 115(9):1703-1708; Elena C et al. Haematologica. 2011 ; 96(1):167-170).

[0194] Raspartercept is a recombinant fusion protein consisting of a modified type IIB activin receptor linked to the Fc domain of human immunoglobulin G1 (IgG1) ( figure 1 ) (Attie KM et al. Am J Hematol. 2014; 89(7):766-770; Suragani RN et al. Nat Med. 2014; 20(4):408-414). Raspartercept acts as an erythroid maturation agent by binding to specific transforming growth factor-beta (TGF-beta) superfamily ligands, such as gro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to view more

Abstract

Provided herein are methods for treating myeloproliferative neoplasm-associated myelofibrosis in a subject, comprising administering to the subject an ActRIIB signaling inhibitor. Also provided hereinare methods for treating myeloproliferative neoplasm-associated myelofibrosis in a subject in need thereof, wherein the method comprises administering to the subject a pharmaceutically effective amount of an ActRIIB signaling inhibitor, and wherein said treating reduces or palliates one or more symptoms of said myeloproliferative neoplasm-associated myelofibrosis in said subject. Also provided herein is a method for treating anemia in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of an ActRIIB signaling inhibitor, wherein the subject has myeloproliferative neoplasm-associated myelofibrosis.

Description

[0001] This application claims the benefit of U.S. Provisional Application No. 62 / 519,725, filed June 14, 2017, and U.S. Provisional Application No. 62 / 679,210, filed June 1, 2018, each of which is incorporated herein by reference in its entirety. [0002] This application incorporates by reference the Sequence Listing submitted together with this application, its text file name is "14247-306-228_SEQ_LISTING.txt", created on June 6, 2018, and its size is 81KB. [0003] 1. Technical field [0004] Provided herein are methods for treating myeloproliferative neoplasms-associated myelofibrosis in a subject comprising administering to the subject an ActRIIB signaling inhibitor. Also provided herein is a method for treating myeloproliferative neoplasm-associated myelofibrosis in a subject in need thereof, wherein the method comprises administering to the subject a pharmaceutically effective amount of an ActRIIB signaling inhibitor, and wherein the treating Alleviating or alleviating ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/519A61K45/06C07K14/495
CPCA61K45/06C12N9/12C07K2319/30C12Y207/1103A61K38/1793A61P35/00A61P7/06A61K9/0019A61K38/179C07K14/71
Inventor 阿伯达拉曼恩·拉亚德姆罗伯特·盖尔
Owner CELGENE CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap